Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases

Cancer Immunology, Immunotherapy

Volumn 65, Issue 10, 2016, Pages 1189-1199

  Mauldin, Ileana S ^a   Wages, Nolan A ^b   Stowman, Anne M ^a   Wang, Ena ^c   Smolkin, Mark E ^b   Olson, Walter C ^a   Deacon, Donna H ^a   Smith, Kelly T ^a   Galeassi, Nadedja V ^a   Chianese‐Bullock, Kimberly A ^a   Dengel, Lynn T ^a   Marincola, Francesco M ^c   Petroni, Gina R ^b   Mullins, David W ^d   Slingluff, Craig L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Human; Immunotherapy; Interferon gamma; Melanoma; T lymphocytes; Tumor vaccines

Indexed keywords

ALPHA1 INTERFERON; CORTICOSTEROID; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HLA A1 ANTIGEN; HLA A11 ANTIGEN; HLA A2 ANTIGEN; HLA A3 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; MACROPHAGE DERIVED CHEMOKINE; MELANOMA VACCINE; RANTES; SECONDARY LYMPHOID TISSUE CHEMOKINE; TRANSFORMING GROWTH FACTOR BETA; CANCER VACCINE; CCL5 PROTEIN, HUMAN; CXCL10 PROTEIN, HUMAN; CXCL11 PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; PEPTIDE FRAGMENT; SUBUNIT VACCINE; TUMOR ANTIGEN;

ARTICLE; CANCER STAGING; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; MALE; MELANOMA METASTASIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SKIN ULCER; T LYMPHOCYTE; TUMOR BIOPSY; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT; TUMOR REJECTION; AGED; CELL CULTURE; CELL MOTION; CLINICAL TRIAL; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; SURVIVAL ANALYSIS; TUMOR ASSOCIATED LEUKOCYTE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL MOVEMENT; CELLS, CULTURED; CHEMOKINE CCL5; CHEMOKINE CXCL10; CHEMOKINE CXCL11; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INTERFERON-GAMMA; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PEPTIDE FRAGMENTS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; VACCINES, SUBUNIT;

EID: 84982106672     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1881-y     Document Type: Article

References (46)

1. Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea S, Dengel LT, Patterson JW, Slingluff CL Jr (2012) Immunotype and immunohistologic characteristics of tumor infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 72(5):1070–1080
2. Gajewski TF, Fuertes M, Spaapen R, Zheng Y, Kline J (2011) Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol 23(2):286–292
3. Bedognetti D, Wang E, Sertoli MR, Marincola FM (2010) Gene-expression profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines 9(6):555–565
4. Bogunovic D, O’Neill DW, Belitskaya-Levy I, Vacic V, Yu YL, Adams S, Darvishian F, Berman R, Shapiro R, Pavlick AC, Lonardi S, Zavadil J, Osman I, Bhardwaj N (2009) Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA 106(48):20429–20434. doi:10.1073/pnas.0905139106
5. Fridman WH, Galon J, Dieu-Nosjean MC, Cremer I, Fisson S, Damotte D, Pages F, Tartour E, Sautes-Fridman C (2011) Immune infiltration in human cancer: prognostic significance and disease control. Curr Top Microbiol Immunol 344:1–24. doi:10.1007/82_2010_46.:1-24
6. Strieter RM, Polverini PJ, Arenberg DA, Kunkel SL (1995) The role of CXC chemokines as regulators of angiogenesis. Shock 4(3):155–160
7. Strieter RM, Belperio JA, Burdick MD, Sharma S, Dubinett SM, Kearns P (2004) CXC chemokines: angiogenesis, immunoangiostasis, and metastases in lung cancer. Ann N Y Acad Sci 1028:351–360
8. + T-cell recruitment. Cancer Res 69(7):3077–3085
9. + T cells is associated with survival in melanoma patients with stage III disease. Cancer Res 64(21):7697–7701
10. Clancy-Thompson E, King LK, Nunnley LD, Mullins IM, Slingluff CL Jr, Mullins DW (2013) Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T cells. Cancer Immunol Res 1(5):332–339. doi:10.1158/2326-6066.cir-13-0084
11. Dengel LT, Norrod AG, Gregory BL, Clancy-Thompson E, Burdick MD, Strieter RM, Slingluff CL Jr, Mullins DW (2010) Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma. J Immunother 33(9):965–974
12. Baird JR, Byrne KT, Lizotte PH, Toraya-Brown S, Scarlett UK, Alexander MP, Sheen MR, Fox BA, Bzik DJ, Bosenberg M, Mullins DW, Turk MJ, Fiering S (2013) Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge. J Immunol 190(1):469–478. doi:10.4049/jimmunol.1201209
13. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410(6832):1107–1111
14. Zhu X, Fallert-Junecko BA, Fujita M, Ueda R, Kohanbash G, Kastenhuber ER, McDonald HA, Liu Y, Kalinski P, Reinhart TA, Salazar AM, Okada H (2010) Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners. Cancer Immunol Immunother 59(9):1401–1409
15. Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, Yagita H, Overwijk WW, Lizee G, Radvanyi L, Hwu P (2012) PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res 72(20):5209–5218. doi:10.1158/0008-5472.CAN-12-1187
16. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF (2013) Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 5(200):200ra116
17. Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, Murphy C, Johansen N, Grosh WW, Yamshchikov GV, Neese PY, Patterson JW, Fink R, Rehm PK (2007) Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res 13(21):6386–6395
18. + T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res 15(22):7036–7044. doi:10.1158/1078-0432.ccr-09-1544
19. Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Ross MI, Haas NB, von Mehren M, Grosh WW (2011) Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol 29(21):2924–2932. doi:10.1200/jco.2010.33.8053
20. + T cells of two formulations of an incomplete Freund’s adjuvant for multipeptide melanoma vaccines. J Immunother 33:630–638
21. Slingluff CL Jr, Petroni GR, Olson WC, Smolkin ME, Chianese-Bullock KA, Mauldin IS, Smith KT, Deacon DH, Varhegyi NE, Donnelly SB, Reed CM, Scott K, Galeassi NV, Grosh WW (2016) A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites. Cancer Immunol Immunother 65(1):25–36. doi:10.1007/s00262-015-1770-9
22. Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, Janetzki S, Ferrari G, Birx DL, Cox JH (2002) A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 260(1–2):157–172
23. Galon J, Angell HK, Bedognetti D, Marincola FM (2013) The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 39(1):11–26
24. Singh M, Overwijk WW (2015) Intratumoral immunotherapy for melanoma. Cancer Immunol Immunother 64(7):911–921. doi:10.1007/s00262-015-1727-z
25. Sadanaga N, Nagoshi M, Lederer JA, Joo HG, Eberlein TJ, Goedegebuure PS (1999) Local secretion of IFN-gamma induces an antitumor response: comparison between T cells plus IL-2 and IFN-gamma transfected tumor cells. J Immunother 22(4):315–323
26. Clancy-Thompson E, Perekslis TJ, Croteau W, Alexander MP, Chabanet TB, Turk MJ, Huang YH, Mullins DW (2015) Melanoma induces, and adenosine suppresses, CXCR3-cognate chemokine production and T-cell infiltration of lungs bearing metastatic-like disease. Cancer Immunol Res 3(8):956–967. doi:10.1158/2326-6066.cir-15-0015
27. Tanese K, Grimm EA, Ekmekcioglu S (2012) The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: its impact on the chemokine expression profile, including suppression of CXCL10. Int J Cancer 131(4):891–901. doi:10.1002/ijc.26451
28. Hong M, Puaux AL, Huang C, Loumagne L, Tow C, Mackay C, Kato M, Prevost-Blondel A, Avril MF, Nardin A, Abastado JP (2011) Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res 71(22):6997–7009
29. Muthuswamy R, Berk E, Junecko BF, Zeh HJ, Zureikat AH, Normolle D, Luong TM, Reinhart TA, Bartlett DL, Kalinski P (2012) NF-kappaB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res 72(15):3735–3743. doi:10.1158/0008-5472.can-11-4136
30. Teramura Y, Watanabe Y, Kan N, Masuda T, Kuribayashi K (1993) Interferon-gamma-producing tumor induces host tumor-specific T cell responses. Jpn J Cancer Res Gann 84(6):689–696
31. Huang H, Liu Y, Xiang J (2002) Synergistic effect of adoptive T-cell therapy and intratumoral interferon gamma-inducible protein-10 transgene expression in treatment of established tumors. Cell Immunol 217(1–2):12–22
32. Yu D, Thomas-Tikhonenko A (2001) Intratumoral delivery of an interferon gamma retrovirus-producing cells inhibits growth of a murine melanoma by a non-immune mechanism. Cancer Lett 173(2):145–154
33. Casrouge A, Decalf J, Ahloulay M, Lababidi C, Mansour H, Vallet-Pichard A, Mallet V, Mottez E, Mapes J, Fontanet A, Pol S, Albert ML (2011) Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest 121(1):308–317. doi:10.1172/jci40594
34. Rainczuk A, Rao JR, Gathercole JL, Fairweather NJ, Chu S, Masadah R, Jobling TW, Deb-Choudhury S, Dyer J, Stephens AN (2014) Evidence for the antagonistic form of CXC-motif chemokine CXCL10 in serous epithelial ovarian tumours. Int J Cancer 134(3):530–541. doi:10.1002/ijc.28393
35. Salerno EP, Shea SM, Olson WC, Petroni GR, Smolkin ME, McSkimming C, Chianese-Bullock KA, Slingluff CL Jr (2013) Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund’s adjuvant, with or without peptide. Cancer Immunol Immunother 62(7):1149–1159. doi:10.1007/s00262-013-1435-5
36. Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, Dorta-Estremera SM, Greeley NR, Nitti G, Peng W, Liu C, Lou Y, Wang Z, Ma W, Rabinovich B, Schluns KS, Davis RE, Hwu P, Overwijk WW (2013) Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion. Nat Med 19(4):465–472
37. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, Lengyel E (2011) Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 17(11):1498–1503. doi:10.1038/nm.2492
38. Nikitenko LL, Brown NS, Smith DM, MacKenzie IZ, Bicknell R, Rees MC (2001) Differential and cell-specific expression of calcitonin receptor-like receptor and receptor activity modifying proteins in the human uterus. Mol Hum Reprod 7(7):655–664
39. Zhang J, Na S, Liu C, Pan S, Cai J, Qiu J (2016) MicroRNA-125b suppresses the epithelial–mesenchymal transition and cell invasion by targeting ITGA9 in melanoma. Tumour Biol 37(5):5941–5949. doi:10.1007/s13277-015-4409-8
40. Wang T, Huang C, Lopez-Coral A, Slentz-Kesler KA, Xiao M, Wherry EJ, Kaufman RE (2012) K12/SECTM1, an interferon-gamma regulated molecule, synergizes with CD28 to costimulate human T cell proliferation. J Leukoc Biol 91(3):449–459. doi:10.1189/jlb.1011498
41. Kuemmerle NB, Rysman E, Lombardo PS, Flanagan AJ, Lipe BC, Wells WA, Pettus JR, Froehlich HM, Memoli VA, Morganelli PM, Swinnen JV, Timmerman LA, Chaychi L, Fricano CJ, Eisenberg BL, Coleman WB, Kinlaw WB (2011) Lipoprotein lipase links dietary fat to solid tumor cell proliferation. Mol Cancer Ther 10(3):427–436. doi:10.1158/1535-7163.mct-10-0802
42. Carter SA, Foster NA, Scarpini CG, Chattopadhyay A, Pett MR, Roberts I, Coleman N (2012) Lipoprotein lipase is frequently overexpressed or translocated in cervical squamous cell carcinoma and promotes invasiveness through the non-catalytic C terminus. Br J Cancer 107(4):739–747. doi:10.1038/bjc.2012.301
43. Platten M, Wick W, Van den Eynde BJ (2012) Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res 72(21):5435–5440. doi:10.1158/0008-5472.can-12-0569
44. Rutkowski MJ, Sughrue ME, Kane AJ, Mills SA, Parsa AT (2010) Cancer and the complement cascade. Mol Cancer Res 8(11):1453–1465. doi:10.1158/1541-7786.mcr-10-0225
45. Spranger S, Gajewski TF (2015) A new paradigm for tumor immune escape: beta-catenin-driven immune exclusion. J Immunother Cancer 3:3. doi:10.1186/s40425-015-0089-6
46. Spranger S, Bao RY, Gajewski TF (2015) Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 523(7559):231–261. doi:10.1038/nature14404